US judge approves Bayer's $7.25 billion Roundup settlement, calling it 'fair, reasonable and adequate'
A Missouri judge, Timothy Boyer, has approved Bayer's $7.25 billion settlement of tens of thousands of US lawsuits alleging its Roundup weedkiller causes cancer, ruling the settlement 'fair, reasonable and adequate'. Bayer's chief executive Bill Anderson called the approval a major step forward; plaintiffs' lawyers were split, some welcoming long-overdue compensation and others calling the settlement not enough. The settlement is not an admission of liability, Bayer maintains Roundup is safe, and the ruling can still be appealed.

Checking in progress
This story is still being checked. Claims below are published as claims — never dressed as facts — and each one moves only when the evidence earns it.
- Collecting reportsDone
- Grouping the versionsDone
- Checking claims4 of 4 claims checked
- 4Human gateWe are here
4 of 4 claims checked so far · step 4 of 4: Human gate
Key points
- Judge Timothy Boyer approved the $7.25 billion settlement, finding it 'fair, reasonable and adequate'.
- The deal covers tens of thousands of claims by people who say they developed non-Hodgkin lymphoma after using Roundup.
- Bayer has faced around 200,000 claims since buying Monsanto in 2018 and has already paid out more than $10 billion; about 200 cases sit outside this settlement.
What happened
Bayer maintains that Roundup is safe and does not cause cancer, and says the settlement is not an admission of liability. The science is contested: the WHO's cancer agency classified glyphosate as 'probably carcinogenic to humans' in 2015, while the US Environmental Protection Agency has said it is 'not likely to be carcinogenic to humans'.
What we know / what we don't know yet
What we know
- The approval, the $7.25 billion total and the judge's finding are established; the parties' reactions are on record.
What we don't know yet
- How much individual claimants will receive and over what period the fund will pay out.
- Whether the approval survives the appeals that some plaintiffs' lawyers say they may bring.
Claim by claim
Show all claims (4)
Why this label: The approval and the judge's words are from DW's report of the ruling, which draws on AFP, AP and Reuters reporting.
On the ladder: a claim earns Verified from primary evidence, or from two independent sources that do not copy each other.
Why this label: The claim counts and the $10 billion figure are as DW reports them, with the 200 outside cases attributed to Bayer.
On the ladder: a claim earns Verified from primary evidence, or from two independent sources that do not copy each other.
Why this label: Each reaction is carried as its maker's position; the appeal possibility is why the story is published in Checking state.
On the ladder: a claim earns Verified from primary evidence, or from two independent sources that do not copy each other.
Why this label: The WHO's IARC classified glyphosate as 'probably carcinogenic to humans' in 2015; the US EPA has said it is 'not likely to be carcinogenic to humans'; Bayer denies Roundup causes cancer. The settlement resolves lawsuits without settling this question and is not an admission of liability.
On the ladder: credible sources conflict, so we show both workings. One side's own statement is that side's position — never proof.
Why it matters
The approval moves one of the largest product-liability fights in US history toward an end — for the tens of thousands of claimants inside the deal, and for Bayer, which has already paid out more than $10 billion. It does not settle the underlying science, on which the WHO's agency and the US regulator still disagree.
Update history
No silent edits. Every change is written here, with its time.
- Latest
Published in Checking state — the approval is established, and the story will be updated if an appeal is filed. The settlement is not an admission of liability.